Trials / Active Not Recruiting
Active Not RecruitingNCT02633111
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 501 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether a blood test can accurately detect whether if the participant's lymphoma has come back after completion of initial chemotherapy treatment for their aggressive B-cell Non-Hodgkin lymphoma. The purpose of the study is to see if MRD in blood samples can potentially replace CT scans after completion of chemotherapy in the future.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | collected at pre-treatment tumor biopsy | to identify the tumor-specific clonotype |
| OTHER | Peripheral blood tests | for MRD analysis at 3, 6, 9, 12, 15, 18, 21, and at relapse (+/- 1 month). |
| DEVICE | PET/CT | at 3, 6, 9, 15, 18, 21 and at relapse(+/- 1 month) |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2026-10-01
- Completion
- 2026-10-01
- First posted
- 2015-12-17
- Last updated
- 2025-11-04
Locations
12 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02633111. Inclusion in this directory is not an endorsement.